The operator of WeKnowDiets.com and other Web sites should clarify that it markets weight-loss supplement MiracleBurn - featured as the "most popular" product and a "customer choice award" winner on the site - according to the Electronic Retailing Self-Regulation Program. Urban Nutrition presented WeKnowDiets.com as a review forum for diet products, though a challenger argued to ERSP that the site "is premised on a deliberate intent to mislead consumers" by disguising ads as independent product reviews. The CBBB program recommended Aug. 11 that the firm disclose its material connection to the products it endorses. New York-based Urban Nutrition said it will "follow the ERSP's recommendations to reinforce several aspects of effective disclosure methods.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
Bridget Dooling, a law school professor who reviewed draft regulations from the FDA and other agencies as an OMB attorney, said prior federal court decisions suggest judges typically defer to agency decisions based in science.
The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.
